Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
A phase 3 trial of PSMA-1007 F-18 run by ABX advanced biochemical compounds GmbH in prostate cancer, now recruiting.
Overview
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer is a phase 3 interventional study registered as NCT06122584 by ABX advanced biochemical compounds GmbH, with 380 participants planned, started 2024-06-13. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
Shares Localised prostate cancer, high and very high risk, Prostate cancer.
- TrialCopper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
Shares Localised prostate cancer, high and very high risk, Prostate cancer.
- AgentIodine-125 brachytherapy seeds
Shares Localised prostate cancer, high and very high risk, Prostate cancer.
- TermBiochemical recurrence (BCR)
Shares Localised prostate cancer, high and very high risk, Fluorine-18, Prostate cancer.
- TrialOSPREY
Shares Localised prostate cancer, high and very high risk, Fluorine-18.
- TrialA Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
Shares Fluorine-18, Prostate cancer.
- TrialLIGHTHOUSE
Shares Localised prostate cancer, high and very high risk, Fluorine-18.
- TrialproPSMA
Shares Localised prostate cancer, high and very high risk, Fluorine-18, Prostate cancer.